Dec 16, 2024 7:00 am EST MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Dec 11, 2024 7:00 am EST MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
Dec 5, 2024 7:00 am EST MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Dec 3, 2024 7:00 am EST MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
Nov 18, 2024 7:00 am EST MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
Oct 24, 2024 7:00 am EDT MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update